4DMedical Limited (4DX) Earnings Call Transcripts

4DMedical Limited's Latest Earnings Call - June 9, 2026

In the second quarter of fiscal year 2026, 4DMedical Limited (4DX:AU) reported significant advancements in commercialization, highlighted by the initiation of the CLEAR study aimed at replacing CT pulmonary angiograms (CTPAs) for diagnosing pulmonary embolism. The company also announced the acquisition of contextflow, enhancing its European market presence, and secured a partnership with SimonMed, a major outpatient imaging center in the U.S. Revenue figures and earnings were not disclosed, but management expressed confidence in accelerating sales driven by these strategic initiatives and a robust pipeline. Guidance remains optimistic, with expectations of increased scan volumes and market penetration over the next 12 months.

Reported metrics

Guidance from management

Management maintained an optimistic outlook, anticipating increased scan volumes and market penetration over the next 12 months, with expectations of significant growth in both the U.S. and European markets.

What management said

Yes, that's right. So the one thing that's there that we that we sometimes that we get -- that we have to get people to is that when we do -- our software like lots of other things in the users what's called an inspiratory, expiratory CT, but that's very standard in the lungs for a doctor to ask to see both. So they ask you to breathe in and they breathe out and literally, on a 5-minute appointment to do a CAT scan. ...

Yes. I think that -- I don't think we'll have any issues with reimbursement. I think one of the things that we've found on that topic -- one of the things that we found is when we're talking to folks about the PE side of things, the C-suite of the hospital tends to get involved because you're directly impacting workflows through the ED and you're directly impacting the hospital's risk of lawsuits and so on from all o...

What analysts pressed on

Analysts expressed concerns regarding the specificity of the CT:VQ exam compared to CTPA, with questions about how the company plans to address potential discrepancies in clinical outcomes. There were also inquiries about the timeline for revenue recognition from the Philips agreement and the impact of short selling on stock performance.

Main topics on the call

• CLEAR Study Initiation — Management announced the launch of the CLEAR study, targeting the replacement of CTPA for pulmonary embolism diagnosis. CEO Andreas Fouras stated, 'we have decided to sort of fast track the fast track that process and ge...
• Acquisition of Contextflow — The acquisition of contextflow for $18 million is aimed at strengthening 4DMedical's foothold in the European medical imaging market. Fouras noted, 'the price could have been better. It was a very good buy from a price s...
• Partnership with SimonMed — 4DMedical secured a three-year agreement with SimonMed, which operates across 170 clinics in the U.S. This partnership is designed to enhance reimbursement pathways and accelerate the adoption of CT:VQ. Matt Tucker empha...
• Market Potential for CTPA Replacement — Management highlighted the significant market opportunity, with 5 million CTPA exams conducted annually in the U.S. Fouras stated, 'if we're not inferior on the clinical side, all of those financial and logistical issues...

Read the full 4DMedical Limited transcript (June 9, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 16 4DMedical Limited earnings call transcripts on record, spanning May 9, 2023 to June 9, 2026. Based on this history, 4DMedical Limited reports quarterly. The most recent call on file is dated June 9, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

4DX

Exchange

ASX

Country

AU

Sector

Health Care

Industry

Health Care Technology

Calls on record

16

First call

May 9, 2023

Most recent

June 9, 2026

Reporting cadence

quarterly